Clinical Trial Update: Study of Cabozantinib Efficacy, Safety and Tolerability in Metastatic Renal Carcinoma in Aged Fragile Patients: CABOMAYOR Study [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating cabozantinib for metastatic renal carcinoma in aged fragile patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Carcinoma

Drugs mentioned

• cabozantinib (cabozantinib)

Snippet

Sponsor: Spanish Oncology Genito-Urinary Group | Conditions: Old Age; Debility, Renal Carcinoma Metastatic | Phase 2 | Status: COMPLETED